A Phase I Trial of WP1066 in Patients With Recurrent Malignant Glioma and Brain Metastasis From Melanoma
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2018
At a glance
- Drugs WP 1066 (Primary)
- Indications Brain metastases; Glioblastoma; Glioma; Malignant melanoma
- Focus Adverse reactions; First in man
- 31 Aug 2018 Biomarkers information updated
- 24 Jul 2018 Status changed from not yet recruiting to recruiting.
- 03 May 2018 Planned End Date changed from 1 Mar 2022 to 1 Jul 2022.